ImageneBio (IMA) news
Recent news
Imagenbio Inc: H.C. Wainwright initiates coverage with buy rating; price target $28
ImageneBio, Inc. (IMA) has recently attracted attention from H.C. Wainwright, which initiated coverage on the biotechnology firm with a "Buy" rating and price target of $28. This move comes amid a series of analyst actions, including Wedbush lowering its price target for ImageneBio to $2, while…
AInvest Wire · Aug 21, 2026Imagenebio - Kristin Yarema had been interim principal financial officer until July 20, 2026 - SEC filing
ImageneBio, Inc. (NASDAQ: IMA) has confirmed that Kristin Yarema, Ph.D., its Chief Executive Officer, served as the interim principal financial officer until July 20, 2026, as disclosed in a recent SEC filing . Dr. Yarema assumed the role following the resignation of former Chief Financial Officer…
AInvest Wire · Jul 23, 2026Imagenbio appoints Matt Robbins as general counsel
ImageneBio has appointed Matt Robbins as its general counsel, bringing extensive experience in healthcare finance and mergers and acquisitions to the leadership team. Robbins is a senior advisor in Kaufman Hall’s Mergers and Acquisitions, Treasury, and Capital Markets practices, where he provides…
AInvest Wire · Jul 7, 2026ImportantTentative tender of non-comps, FIMA for 4-week bills total $8.1 bln; competitive remaining $66.9 bln
AInvest Wire · Jun 4, 2026ImportantHong Kong large-AI-model concept stocks extended losses; Zhipu (02513.HK) fell over 10%, MINIMAX-W (00100.HK) fell over 7%
AInvest Wire · Jun 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.